

A randomised study of Mitomycin, Vinblastine and Platinum (cisplatin) (MVP) three versus six cycles in advanced Non-Small Cell Lung Cancer (NSCLC)

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 16/04/2019	Condition category Cancer	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

ClinicalTrials.gov (NCT)
NCT00004209

Protocol serial number
95.24

Study information

Scientific Title

A randomised study of Mitomycin, Vinblastine and Platinum (cisplatin) (MVP) three versus six cycles in advanced Non-Small Cell Lung Cancer (NSCLC)

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Lung (non-small cell) cancer

Interventions

Cisplatin 50 mg/m² Mitomycin-C 8 mg/m² intravenous (iv) day one
Vinblastine 6 mg/m² iv day one

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Mitomycin, vinblastine and platinum (cisplatin)

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

30/11/1998

Eligibility

Key inclusion criteria

1. Histological evidence of NSCLC
2. Stage IIIb or IV disease not eligible for surgery or radical radiotherapy
3. Performance status zero, one or two
4. Ability to give signed, informed consent
5. ⁵¹Cr Ethylene Diamine Tetraacetic Acid (EDTA) more than 60 ml/min, creatinine clearance more than 60 ml/min, Haemoglobin (Hb) more than 10 g/dl, White Cell Count (WCC) more than $3 \times 10^9/l$, platelets $100 \times 10^{12}/l$, Liver Function Tests (LFTs) not more than two times normal unless due to metastatic disease

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Total final enrolment

308

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1993

Date of final enrolment

30/11/1998

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Cancer Research UK (CRUK) (UK)

ROR

<https://ror.org/054225q67>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2001	16/04/2019	Yes	No